Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
The FDA warned diabetes patients of the risks of using homegrown treatment devices, such as unrecognized combos of CGMs and insulin pumps.
The FBI has launched its own probe into some of the world’s largest medtech companies, stemming from a Brazilian corruption case, Reuters reports.
J&J’s electrophysiology-focused Biosense Webster division launched a cloud-based network to link up the field’s myriad devices and share their data.
Abbott pledged to provide its neuromodulation tech for the public-private NIH research effort.
Ginkgo Bioworks is buying Warp Drive Bio’s genome mining team, tech and database, eyeing the platform for use in next-gen antibiotics.
Thermo Fisher found that its blood tests could monitor the changing genetics of lung tumors and illustrate developments in drug resistance over time.
ArcherDX has closed on a $60 million financing round to support its companion diagnostic program spanning solid and blood tumors.
Grail’s multicancer blood test has taken a helpful step closer to approval, by obtaining a breakthrough device designation from the FDA.
Zebra Medical received an FDA go-ahead to use AI to quickly scour X-rays and alert clinicians for signs of pneumothorax.
AliveCor has secured an FDA clearance for its personal device offering six leads, providing more detailed views into heartbeats and arrhythmias.
